Sutro Biopharma (STRO) — Cash Flow Reinvestment Rate

Latest as of June 2024: 8.58x

Sutro Biopharma (STRO) has a Cash Flow Reinvestment Rate of 8.58x as of June 2024, reinvesting $81.13 Million (capex $756.00K plus investments $-80.38 Million) from operating cash flow of $9.46 Million. See Sutro Biopharma free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.

Reinvestment Rate

8.58x
(Capex + Investments) / Operating CF

Total Reinvested

$81.13 Million
Capex + Investments

Operating Cash Flow

$9.46 Million
USD

Capital Expenditures

$756.00K
USD

Sutro Biopharma Cash Flow Reinvestment Rate (2018–2022)

Historical reinvestment intensity for Sutro Biopharma across 2 annual periods. For the full cash flow conversion analysis, see Sutro Biopharma cash conversion from operations.

Annual Cash Flow Reinvestment Rate for Sutro Biopharma (2018–2022)

Year-by-year capital reinvestment analysis for Sutro Biopharma. See Sutro Biopharma leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.

Year Reinvestment Rate Total Reinvested (USD) Operating CF Capex YoY Change
2022 12.08x $42.88 Million $3.55 Million $7.86 Million ▲ +90.9%
2018 6.33x $80.27 Million $12.68 Million $1.56 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow